Today we are launching this year's Alantra Pharma Fast 50, which ranks 2017's fastest-growing, privately owned pharmaceutical businesses in the UK.
The UK pharma industry is a world-leader in R&D and innovation, and despite the challenges facing the sector, including the rigours of Brexit and unprecedented pressure on pricing from both governments and insurers, it continues to provide an opportunity for agile businesses to flourish. However, it is smaller and more nimble businesses that are likely to be able to adapt most quickly to exploit these opportunities. That is reflected in the Alantra Pharma Fast 50.
The Pharma Fast 50 places the spotlight on the leading companies in the sector, ranging from pharma outsourcing and development businesses to consultants and pharmacies. These companies are bringing innovative products and services to market, taking advantage of the opportunities which the trends underpinning the pharma industry and global demand for medicines are creating.
The first look at this year's Pharma Fast 50 is provided by the Pharma Times in their March exclusive. Over the coming month we will be issuing the full Pharma Fast 50 report which includes in-depth reviews of each subsector and further discussion with some of the constituent businesses.
We published the report for the first time last year as the Catalyst Pharma Fast 50. Since then we have merged with Alantra, the global investment bank. Ahead of Catalyst rebranding to Alantra in the coming weeks, we have launched this year’s list under the Alantra brand name.
PharmaTimes presents Alantra’s annual look at the fastest-growing pharma companies At a time of unprecedented pressure on pricing from both governments and insurers, it might seem counter-intuitive to describe pharmaceuticals as a growth industry. Yet for all the challenges facing the sector – Brexit, regulatory scrutiny, changing patient demands and the tyranny of the patent cliff – pharma continues to offer exciting opportunities to the most agile businesses. The drivers of growth are as strong as ever, demographic trends are a powerful force, as the population ages, and new opportunities in areas such as digital health, personalised medicine, outsourcing and preventative medicine are emerging rapidly. However, it is smaller and more nimble businesses that are likely to be able to adapt most quickly to exploit these opportunities. That is reflected in our Alantra Pharma Fast 50.